Teams

Immuno-inflammatory Diseases

During the past decade, novel revolutionary frontiers have been opened at the immuno-inflammatory research fields. Indeed, with the help of modern, state-of-the-art technologies (immunomics and other omics, systems biology) it was identified that the immune system is much more complex than previously thought and that its proper functions are defined by multi-directional intercellular communications between cellular (and humoral) components of innate and adaptive immunity.

Group Name

Group Leader

Details

Edit Buzás MD, PhD, DSc

Edit Buzás MD, PhD, DSc

VIDEO INTRODUCTION >

Balázs Enyedi MD, PhD

VIDEO INTRODUCTION >

Attila Gácser PhD, DSc

VIDEO INTRODUCTION >
Prof. Lajos Kemény MD

Prof. Lajos Kemény MD

VIDEO INTRODUCTION >
Bálint Kintses

Bálint Kintses PhD

VIDEO INTRODUCTION >
József Maléth

József Maléth MD, PhD

VIDEO INTRODUCTION >

Metabolic and Cardiovascular Diseases

Metabolic and cardiovascular (CV) diseases are among the major cause of death in Hungary and worldwide, thus impose an enormous social and economic burden. In the clinical practice there is a great need for i) the elucidation of the molecular pathomechanism of such high-burden diseases (including obesity, diabetes, heart failure), as well as for ii) the development of novel therapies, cost-effective treatments and iii) more personalized or at least targeted therapeutic approaches.

Group Name

Group Leader

Details

László Csanády

László Csanády MD, PhD, DSc

VIDEO INTRODUCTION >

Nazha Hamdani PhD

VIDEO INTRODUCTION >
Balázs Papp

Balázs Papp PhD

VIDEO INTRODUCTION >
Zoltán Varga

Zoltán Varga MD, PhD

VIDEO INTRODUCTION >
Nikolett Wohner MD

Nikolett Wohner MD, PhD

VIDEO INTRODUCTION >

Lamsa Karri PhD., Dr MTA

VIDEO INTRODUCTION >

Balazs Németh MD, PhD

VIDEO INTRODUCTION >

Genomic Instability and Cancer

In the EU-28, cancer accounts for 25.8% of the total number of deaths, acquiring the second position behind cardiovascular diseases. In 2012, among the EU member states, the highest standardized death rates for cancer were recorded in Hungary and Croatia, both with rates over 330 per 100 000 inhabitants (EuroStat data). During the past decade(s), significant developments have been made to lower the burdens related to cancer and its complications.

Group Name

Group Leader

Details

Antal Berényi

Antal Berényi MD, PhD

VIDEO INTRODUCTION >
Csaba Bödör

Csaba Bödör PhD

VIDEO INTRODUCTION >

Tibor Pankotai PhD

VIDEO INTRODUCTION >

Máté Manczinger PhD

VIDEO INTRODUCTION >

Lőrinc Sándor Pongor, PhD

VIDEO INTRODUCTION >

Lajos Vince Kemény MD, PhD

VIDEO INTRODUCTION >

Szilvia Juhász PhD

VIDEO INTRODUCTION >

Infectious Diseases with special emphasis on Co-Morbidities

Three of HCEMMs Research Pillars are focused on non-infective chronic diseases, which are the main causes of non-natural death in Hungary. Often, these conditions (e.g. cancers, heart diseases or immuno-degenerative diseases) are made worse in the end stages due to infectious diseases. This includes bacterial infections, such as sepsis or pneumonia, viral infections (for example COVID-19) and fungal infections (e.g. fungal sepsis). HCEMM groups are working on the accurate and early diagnosis of such co-morbidities and also on the creation of new treatment options, which complement the already established treatment regimes. This is especially important in areas, where the current treatment does not work, for example when patients are infected by antibiotic-resistant strains.

Group Name

Group Leader

Details

Dr. Christoph W. Sensen's photo

Dr. Christoph W. Sensen

VIDEO INTRODUCTION >

Viktória Lázár PhD

VIDEO INTRODUCTION >

Clinical Research Groups

Translating research into applied medicine is central to HCEMM’s mission. Conducting clinical research, however, is a task that calls for specialized knowledge and significant resources, often beyond the capacity of individual research groups. Beyond pursuing individual research, HCEMM Clinical Research Groups facilitate the translational aspect of medical research by providing other research groups with the expertise, know-how, regulatory background and the technical capacity for sample collection, storage, clinical trials, and subsequent analyses.

Group Name

Group Leader

Details

Balázs Bende, MD

VIDEO INTRODUCTION >

Klaudia Farkas MD, PhD

VIDEO INTRODUCTION >

Balázs Győrffy MD, PhD

VIDEO INTRODUCTION >

Advanced Core Facilities

A key component of the operational model for HCEMM is the co-development of Advanced Core Facilities (ACFs) aligned with the strengths of the founding institutions. The HCEMM ACF model follows the modus operandi of the EMBL core facilities. The main goal is to optimally support researchers with a high measurement volume and a low error rate, so that the efficiency of HCEMM’s research groups is increased in terms of excellence (output of high-quality scientific papers) and sustainability (ability to generate income by competitive grants, spin-offs and technology transfer agreements). In order to achieve these goals, research groups are encouraged to use the equipment of the ACFs instead of purchasing their own, which results in a more efficient use of resources, avoiding unnecessary duplications and improving the utilization of measurement capacities.

The ACFs presents a range of services tailored to the requirements of HCEMM researchers. Simultaneously, it also serves as an EU-level infrastructural, competence and training base that offers its capacities for any Hungarian and EMBL partner researcher as well as for external users.

The HCEMM ACFs provide clear benefits to researchers, such as:

  • experienced and highly educated staff that can help in setting up and executing experiments
  • large variety of research infrastructure, unaffordable by single research groups
  • infrastructure maintenance and renewal that is covered by contracts with vendors
  • professional user management and pay per system usage

The ACFs serve as a bridge between the research groups involved in technology development and future users who expect to utilize novel technology achievements in their mature form. The ACF network builds on the expertise of research groups, but its advanced technologies will be developed towards streamlining their utilization by a larger userbase. An important focus of the HCEMM is to bring our ACF network into direct contact with research groups and companies developing interesting, applicable technologies.

Our ACFs are established in Szeged and Budapest, so that they provide the best support to the HCEMM founding institutions located in these cities.

Group Name

Group Leader

Details

Ferhan Ayaydin

Ferhan Ayaydin PhD

VIDEO INTRODUCTION >
Zsuzsanna Darula

Zsuzsanna Darula PhD

VIDEO INTRODUCTION >
Domokos Máthé

Domokos Máthé DVM PhD

VIDEO INTRODUCTION >

Gergely Röst PhD

VIDEO INTRODUCTION >
This website uses cookies. For more information visit the Cookies & Privacy Policy page.
Skip to content